A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation

NCT00266552 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Conduct Disorder
Disruptive Behavior Disorder
Oppositional Defiant Disorder

Interventions

DRUG: risperidone

Sponsor

Janssen Pharmaceutica N.V., Belgium